HUE036655T2 - Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen - Google Patents

Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen

Info

Publication number
HUE036655T2
HUE036655T2 HUE11751244A HUE11751244A HUE036655T2 HU E036655 T2 HUE036655 T2 HU E036655T2 HU E11751244 A HUE11751244 A HU E11751244A HU E11751244 A HUE11751244 A HU E11751244A HU E036655 T2 HUE036655 T2 HU E036655T2
Authority
HU
Hungary
Prior art keywords
monoclonal antibodies
antibodies against
optimized monoclonal
against tfpi
tfpi
Prior art date
Application number
HUE11751244A
Other languages
English (en)
Hungarian (hu)
Inventor
Peter Scholz
Zhuozhi Wang
Junliang Pan
Joanna Grudzinska
Christian Votsmeier
Jan Tebbe
Joerg Birkenfeld
Nina Wobst
Simone Brueckner
Susanne Steinig
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44542552&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE036655(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of HUE036655T2 publication Critical patent/HUE036655T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Filtering Materials (AREA)
HUE11751244A 2010-03-01 2011-03-01 Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen HUE036655T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30929010P 2010-03-01 2010-03-01

Publications (1)

Publication Number Publication Date
HUE036655T2 true HUE036655T2 (hu) 2018-07-30

Family

ID=44542552

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE11751244A HUE036655T2 (hu) 2010-03-01 2011-03-01 Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
HUE17172199A HUE047173T2 (hu) 2010-03-01 2011-03-01 Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE17172199A HUE047173T2 (hu) 2010-03-01 2011-03-01 Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen

Country Status (37)

Country Link
US (3) USRE47150E1 (enExample)
EP (2) EP3345615B1 (enExample)
JP (4) JP6025570B2 (enExample)
KR (4) KR101807894B1 (enExample)
CN (5) CN102939098B (enExample)
AU (1) AU2011223710B2 (enExample)
BR (1) BR112012022258A2 (enExample)
CA (3) CA2976671C (enExample)
CL (2) CL2012002415A1 (enExample)
CO (1) CO6620068A2 (enExample)
CR (1) CR20120453A (enExample)
CU (1) CU23982B1 (enExample)
CY (2) CY1119410T1 (enExample)
DK (2) DK3345615T3 (enExample)
DO (1) DOP2012000239A (enExample)
EA (2) EA032189B9 (enExample)
EC (2) ECSP12012134A (enExample)
ES (2) ES2765418T3 (enExample)
GT (1) GT201200252A (enExample)
HK (2) HK1232232A1 (enExample)
HR (2) HRP20171472T1 (enExample)
HU (2) HUE036655T2 (enExample)
IL (3) IL221551B (enExample)
LT (2) LT3345615T (enExample)
ME (2) ME03578B (enExample)
MX (2) MX2012010198A (enExample)
MY (1) MY174760A (enExample)
NZ (2) NZ602115A (enExample)
PE (1) PE20160538A1 (enExample)
PH (4) PH12012501742A1 (enExample)
PL (2) PL3345615T3 (enExample)
PT (2) PT3345615T (enExample)
RS (2) RS59830B1 (enExample)
SG (3) SG183443A1 (enExample)
SI (2) SI3345615T1 (enExample)
SM (1) SMT201700454T1 (enExample)
WO (1) WO2011109452A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
DK2379600T4 (da) † 2008-12-22 2021-01-04 Novo Nordisk As Antistoffer mod tissue factor pathway inhibitor
PH12012501742A1 (en) * 2010-03-01 2022-03-21 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
CN103080135B (zh) * 2010-06-30 2017-06-13 诺沃—诺迪斯克有限公司 能够特异性结合组织因子途径抑制剂的抗体
DK2694544T3 (en) * 2011-04-01 2019-04-15 Bayer Healthcare Llc MONOCLONAL ANTIBODIES AGAINST TIBI FACTOR ACTIVITY INHIBITOR (TFPI)
CN104185474B (zh) * 2012-03-30 2017-08-25 拜尔健康护理有限责任公司 蛋白酶调节的抗体
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
HUE037907T2 (hu) 2013-03-15 2018-09-28 Bayer Healthcare Llc TFPI elleni, pH-tartományon belül különbözõ kötõdésû antitestváltozatok javított farmakokinetika érdekében
TW201522368A (zh) * 2013-03-15 2015-06-16 Bayer Healthcare Llc 抗組織因子路徑抑制劑之前藥抗體
CN112225812B (zh) * 2015-02-25 2024-08-13 财团法人牧岩生命科学研究所 结合tfpi的新型抗体以及包含所述抗体的组合物
KR102438650B1 (ko) 2015-08-19 2022-08-31 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
BR112021006223A2 (pt) * 2018-10-11 2021-07-06 Pfizer regime de dosagem para antagonistas de inibidor da via de fator tecidual (tfpi)
KR102692277B1 (ko) * 2019-03-11 2024-08-05 현대자동차주식회사 상용 전기차용 모터 마운트
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
WO2022103221A1 (ko) * 2020-11-13 2022-05-19 한미약품 주식회사 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신장질환 예방 및 치료 용도
CN117285632A (zh) * 2022-06-17 2023-12-26 安源医药科技（上海）有限公司 针对tfpi的单克隆抗体及其用途

Family Cites Families (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1064396A (en) 1975-02-18 1979-10-16 Myer L. Coval Fractional precipitation of gamma globulin with polyethylene glycol
US4075193A (en) 1976-11-26 1978-02-21 Parke, Davis & Company Process for producing intravenous immune globulin
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
DE3782737T3 (de) 1987-08-21 1999-05-20 Imcera Group Inc., Northbrook, Ill. Stabilisierung von Wachstumshormonen.
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
WO1989011297A1 (en) 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
WO1990011091A1 (en) 1989-03-27 1990-10-04 Centocor, Inc. FORMULATIONS FOR STABILIZING OF IgM ANTIBODIES
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US5217954A (en) 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US6165467A (en) 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
EP0539975A1 (en) 1991-10-31 1993-05-05 Teijin Limited Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
US5849700A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
DE4223132A1 (de) 1992-07-14 1994-01-20 Deutsche Aerospace Verfahren zur Schrittakt-Regeneration bei der Demodulation von digital modulierten Signalen und Anordnung zum Ausführen des Verfahrens
JPH06153985A (ja) 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
WO1994019020A1 (en) 1993-02-23 1994-09-01 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
JPH0875736A (ja) 1994-09-06 1996-03-22 Chemo Sero Therapeut Res Inst ヒト組織因子凝固系インヒビターの定量法
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
US6111079A (en) 1995-06-05 2000-08-29 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefore
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
NZ500539A (en) 1995-07-27 2001-11-30 Genentech Inc An antibody that binds HER2 receptor in a composition for treating endometrial, lung, colon or bladder cancer
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US6686191B1 (en) 1995-09-22 2004-02-03 Bayer Healthcare Llc Preparation of virally inactivated intravenously injectable immune serum globulin
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
JP3681206B2 (ja) * 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
DE59710863D1 (de) 1996-01-25 2003-11-20 Schering Ag Verbesserte kontrastmittenlösungen für die intravasale anwendung
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US20040052799A1 (en) 1996-11-15 2004-03-18 Astra Aktiebolag Nucleic acid and amino acid sequences relating to Helicobacter pylori for diagnostics and therapeutics
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6593291B1 (en) 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
US6423316B1 (en) 1997-03-26 2002-07-23 Imperial College Innovative Limited Anticoagulant fusion protein anchored to cell membrane
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6531298B2 (en) 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
US6617156B1 (en) 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
DE59806877D1 (de) 1997-08-21 2003-02-13 Siemens Ag Verfahren zum übertragen von nutzdaten, die unterschiedlichen anwendungen zuordenbar sind
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
EP1062236A4 (en) 1998-03-12 2005-03-23 Human Genome Sciences Inc 31 HUMAN SECRETED PROTEINS
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US20100293669A2 (en) 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
EP1491208B1 (en) 1999-10-04 2010-04-14 Novartis Vaccines and Diagnostics, Inc. Stabilized liquid pharmaceutical compositions containing TFPI
US20050208558A1 (en) 1999-10-19 2005-09-22 Applera Corporation Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof
JP4623825B2 (ja) 1999-12-16 2011-02-02 協和発酵バイオ株式会社 新規ポリヌクレオチド
US20020160934A1 (en) 2000-01-14 2002-10-31 Julie Broadus Nucleic acid sequences from Drosophila melanogaster that encode proteins essential for larval viability and uses thereof
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
WO2001064241A1 (en) 2000-02-29 2001-09-07 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
WO2001076621A2 (en) 2000-04-07 2001-10-18 Kline Ellis L Methods and compositions for treating neoplasms
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US7834146B2 (en) 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
US20040181830A1 (en) 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US20020082206A1 (en) 2000-05-30 2002-06-27 Leach Martin D. Novel polynucleotides from atherogenic cells and polypeptides encoded thereby
EP2281842A1 (en) 2000-06-16 2011-02-09 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
WO2002011753A1 (en) 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
EP1314437B1 (en) 2000-08-11 2014-06-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
EP1930024A3 (en) 2000-09-01 2008-08-06 Chugai Seiyaku Kabushiki Kaisha G-CSF solution formulations having long-term stability
CA2423227C (en) 2000-10-12 2011-11-29 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6912470B2 (en) 2001-05-21 2005-06-28 Ecopia Biosciences, Inc. Genes and proteins involved in the biosynthesis of enediyne ring structures
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
GB0101879D0 (en) 2001-01-24 2001-03-07 Enzyme Res Lab Ltd Anticoagulants and their uses
KR20030085528A (ko) 2001-02-07 2003-11-05 앵스띠뛰 파스퇴르 포토랍두스 루미네센스 균주 ｔｔ01 게놈 및 그 용도
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US6891085B2 (en) 2001-04-20 2005-05-10 Pioneer Hi-Bred International, Inc. Nucleic acid encoding the FUS6 antimicrobial polypeptide of Agrotis ipsilon and its use to enhance disease resistance in a plant
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
DE60235013D1 (de) 2001-07-25 2010-02-25 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
KR20050036852A (ko) 2001-10-15 2005-04-20 기린 비루 가부시키가이샤 항-ｈｌａ-ｄｒ 항체
BR0213298A (pt) 2001-10-16 2006-11-07 Rxkinetix Inc formulações com alta concentração de proteìna e processo de fabricação
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US20030166004A1 (en) 2001-11-01 2003-09-04 Jeno Gyuris Endothelial-cell binding peptides for diagnosis and therapy
PT1441589E (pt) 2001-11-08 2012-08-13 Abbott Biotherapeutics Corp Formulação farmacêutica líquida estável de anticorpos igg
EP1461353A4 (en) 2001-11-29 2006-05-03 Wyeth Corp OPEN READING FRAMES (ORF) OF BACTERIUM ALLOIOCOCCUS OTITIDIS ENCODING ANTIGENIC POLYPEPTIDES, IMUNOGENIC COMPOSITIONS, AND USES THEREOF
US20030138416A1 (en) 2001-12-03 2003-07-24 Jesper Lau Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
US20050108791A1 (en) 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
US7452539B2 (en) 2001-12-19 2008-11-18 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
US20030157082A1 (en) 2002-01-31 2003-08-21 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules
AU2003211991B2 (en) 2002-02-14 2008-08-21 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution formulations
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
SI1946776T1 (sl) 2002-02-27 2017-07-31 Immunex Corporation Stabiliziran tnfr-fc sestavek, ki obsega arginin
WO2003076575A2 (en) 2002-03-04 2003-09-18 Fidelity Systems, Inc., Et Al. The complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
US7074559B2 (en) 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
AU2003251592A1 (en) 2002-06-21 2004-01-06 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
CA2490280A1 (en) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
EP1539212A4 (en) 2002-07-12 2007-05-02 Medarex Inc METHOD AND COMPOSITIONS FOR PREVENTING OXIDATIVE DEGRADATION OF PROTEINS
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
DE10239073A1 (de) 2002-08-26 2004-03-11 Basf Ag Verfahren zur fermentativen Herstellung schwefelhaltiger Feinchemikalien
WO2004032870A2 (en) 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
KR100542401B1 (ko) 2002-10-23 2006-01-11 한국전자통신연구원 인터넷 차별 서비스 망에서의 연결 수락 제어방법
WO2004050850A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to phospholipase a2 and uses thereof
WO2004055164A2 (en) 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
HUE026089T2 (hu) 2002-12-24 2016-05-30 Rinat Neuroscience Corp NGF elleni antitestek és eljárás alkalmazásukra
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
JP4829105B2 (ja) 2003-03-07 2011-12-07 ヴェレニウム コーポレイション ヒドロラーゼ、それをコードする核酸並びにその製造および使用方法
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
KR101195295B1 (ko) 2003-04-04 2012-10-29 노파르티스 아게 고농도 항체 및 단백질 제형
CN1930187B (zh) * 2003-06-27 2015-08-19 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
NZ544751A (en) 2003-07-15 2009-05-31 Amgen Inc Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
KR20110129988A (ko) 2003-07-18 2011-12-02 암젠 인코포레이티드 간세포 성장인자에 결합하는 특이 결합제
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
US20060107345A1 (en) 2003-09-30 2006-05-18 Nickolai Alexandrov Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
CN100522998C (zh) 2003-10-01 2009-08-05 协和发酵麒麟株式会社 抗体的稳定化方法和被稳定的溶液状抗体制剂
CA2445743A1 (en) 2003-10-08 2005-04-08 The University Of British Columbia Methods for modulating neuronal responses
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
US7855274B2 (en) 2003-12-03 2010-12-21 University Of Rochester Recombinant factor VIII having increased specific activity
ES2553987T3 (es) 2003-12-25 2015-12-15 Kyowa Hakko Kirin Co., Ltd. Preparación farmacéutica de base acuosa estable que contiene anticuerpo
EP3018140A3 (en) 2004-01-09 2016-08-17 Basf Se Inactivation of glutamylpolypeptide synthesis in bacillus
US20060041961A1 (en) 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
CA2568162C (en) 2004-05-27 2013-04-16 Crucell Holland B.V. Binding molecules capable of neutralizing rabies virus and uses thereof
CA2564791A1 (en) 2004-06-14 2005-12-29 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
AU2005271892A1 (en) 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
US20060075522A1 (en) 2004-07-31 2006-04-06 Jaclyn Cleveland Genes and uses for plant improvement
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101128483B (zh) 2004-12-21 2015-06-03 阿斯利康公司 血管生成素-2的抗体及其应用
US20080148432A1 (en) 2005-12-21 2008-06-19 Mark Scott Abad Transgenic plants with enhanced agronomic traits
AU2006208286A1 (en) 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
MX2007008719A (es) 2005-01-27 2007-09-11 Novimmune Sa Anticuerpos anti-interferon gamma y metodos de uso de los mismos.
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US20060210557A1 (en) 2005-01-28 2006-09-21 Donna Luisi Stabilized liquid polypeptide formulations
MX2007009545A (es) 2005-02-08 2008-03-11 Genzyme Corp Anticuerpos para tgfbeta.
US8088976B2 (en) 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
WO2006092449A2 (en) 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
US7682808B2 (en) 2005-03-04 2010-03-23 The Board Of Trustees Of The University Of Illinois Coagulation and fibrinolytic cascades modulator
EP1858552A2 (en) 2005-03-08 2007-11-28 Pharmacia & Upjohn Company LLC Composition comprising human igg2 antibody and a chelating agent
CA2600601A1 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Anti-m-csf antibody compositions having reduced levels of endotoxin
KR101280273B1 (ko) 2005-04-18 2013-07-15 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 안정화된 항-ｂ형 간염 바이러스 (ｈｂｖ) 항체 제형
US7889636B2 (en) 2005-05-24 2011-02-15 Cisco Technology, Inc. System and method for implementing a mid-call policy in a RSVP environment
GB2426887B (en) 2005-06-04 2009-01-07 Ibm Client responsibilities in messaging systems
EP2264161A1 (en) 2005-07-02 2010-12-22 Arecor Limited Stable aqueous systems comprising proteins
MX336033B (es) 2005-08-03 2016-01-07 Immunogen Inc Formulaciones de inmunoconjugado.
CA2618068C (en) 2005-08-05 2016-02-16 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US20070086433A1 (en) 2005-10-19 2007-04-19 Cunetto Philip C Methods and apparatus for allocating shared communication resources to outdial communication services
CA2630349A1 (en) 2005-11-21 2007-05-24 Sanofi Pasteur Limited Stabilizing formulations for recombinant viruses
RU2470941C2 (ru) 2005-12-02 2012-12-27 Дженентек, Инк. Связывающие полипептиды и их применения
US7669228B2 (en) 2005-12-27 2010-02-23 Cisco Technology, Inc. System and method for changing network behavior based on presence information
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
WO2007092772A2 (en) 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
DE102006005094A1 (de) 2006-02-04 2007-08-09 Degussa Gmbh Titandioxid und Polycarboxylatether enthaltende Dispersion
US20070224627A1 (en) 2006-03-23 2007-09-27 Lawrence Horowitz Facilitation of translocation of molecules through the gastrointestinal tract
AU2007260787A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc IL-17 and IL-23 antagonists and methods of using the same
WO2007147001A2 (en) 2006-06-14 2007-12-21 Imclone Systems Incorporated Lyophilized formulations of anti-egfr antibodies
DK2426150T3 (en) 2006-06-30 2018-01-22 Novo Nordisk As ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
US8355333B2 (en) 2006-08-31 2013-01-15 Ciena Corporation Methods and systems for session initiation protocol control of network equipment
EP2076287A2 (en) 2006-10-12 2009-07-08 Wyeth Methods and compositions with reduced opalescence
CN101553504A (zh) 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
CN101678103A (zh) 2007-03-30 2010-03-24 米迪缪尼股份有限公司 抗体制剂
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
LT2170390T (lt) 2007-06-14 2019-01-10 Biogen Ma Inc. Natalizumabo antikūnų kompozicijos
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
US8236316B2 (en) * 2007-11-21 2012-08-07 Oregon Health & Science University Anti-factor XI monoclonal antibodies and methods of use thereof
US9308257B2 (en) 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
PT2222706E (pt) 2007-12-14 2014-07-28 Novo Nordisk As Anticorpos contra nkg2d humano e utilizações dos mesmos
UA101487C2 (en) 2007-12-21 2013-04-10 Ф. Хоффманн-Ля Рош Аг Humanized b-ly1 antibody formulation
RU2470628C2 (ru) 2007-12-28 2012-12-27 Биоинвент Интернешнл Аб Состав
EP2254911B1 (en) 2008-02-20 2015-11-25 Novo Nordisk A/S Humanized anti-c5ar antibodies
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
WO2010000721A1 (en) 2008-06-30 2010-01-07 Novo Nordisk A/S Anti-human interleukin-20 antibodies
UA112050C2 (uk) 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
SI2331090T1 (en) 2008-09-19 2018-04-30 Pfizer Inc. Stable liquid antibody formulation
NZ606283A (en) 2008-11-28 2014-08-29 Abbvie Inc Stable antibody compositions and methods for stabilizing same
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
NZ593815A (en) 2008-12-19 2013-05-31 Tissue factor pathway inhibitor (tfpi) inhibitors and methods of use
CN102300876A (zh) 2008-12-22 2011-12-28 诺沃—诺迪斯克有限公司 针对组织因子途径抑制剂(tfpi)的抗体
DK2379600T4 (da) 2008-12-22 2021-01-04 Novo Nordisk As Antistoffer mod tissue factor pathway inhibitor
PE20120359A1 (es) 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
AU2010263058A1 (en) 2009-06-18 2012-01-12 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
HRP20251316T1 (hr) 2009-09-03 2025-12-05 Ablynx Nv Stabilne formulacije polipeptida i njihova upotreba
EP2332995A1 (en) 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
PH12012501742A1 (en) * 2010-03-01 2022-03-21 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
DK2547355T3 (en) 2010-03-19 2017-03-20 Baxalta GmbH TFPI INHIBITORS AND METHODS OF USE
MX2012013586A (es) 2010-05-28 2013-01-24 Novo Nordisk As Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante.
JP6002691B2 (ja) 2011-02-11 2016-10-05 バクスアルタ ゲーエムベーハー 組織因子経路阻害剤に対するアプタマーおよび出血障害治療薬としてのそれらの使用
DK2694544T3 (en) 2011-04-01 2019-04-15 Bayer Healthcare Llc MONOCLONAL ANTIBODIES AGAINST TIBI FACTOR ACTIVITY INHIBITOR (TFPI)
US20130267584A1 (en) 2012-03-22 2013-10-10 Baxter Healthcare S.A. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
HUE037907T2 (hu) 2013-03-15 2018-09-28 Bayer Healthcare Llc TFPI elleni, pH-tartományon belül különbözõ kötõdésû antitestváltozatok javított farmakokinetika érdekében
CN112225812B (zh) 2015-02-25 2024-08-13 财团法人牧岩生命科学研究所 结合tfpi的新型抗体以及包含所述抗体的组合物
KR102438650B1 (ko) 2015-08-19 2022-08-31 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도

Also Published As

Publication number Publication date
HRP20171472T1 (hr) 2017-12-01
EP2542257B1 (en) 2017-07-05
KR101807894B1 (ko) 2017-12-12
CO6620068A2 (es) 2013-02-15
KR20190047135A (ko) 2019-05-07
KR20170137218A (ko) 2017-12-12
DK2542257T3 (en) 2017-10-16
EA032189B9 (ru) 2019-09-30
EA032189B1 (ru) 2019-04-30
SI3345615T1 (sl) 2020-03-31
MX354743B (es) 2018-03-16
ECSP12012134A (es) 2012-09-28
NZ702494A (en) 2016-09-30
LT3345615T (lt) 2020-02-10
JP2020115868A (ja) 2020-08-06
RS56409B1 (sr) 2018-01-31
PL3345615T3 (pl) 2020-07-13
KR20180091116A (ko) 2018-08-14
KR101903931B1 (ko) 2018-10-02
IL221551B (en) 2019-08-29
KR101974980B1 (ko) 2019-05-07
RS59830B1 (sr) 2020-02-28
SG10201502587SA (en) 2015-06-29
US9309324B2 (en) 2016-04-12
JP6684369B2 (ja) 2020-04-22
CN102939098B (zh) 2016-08-03
MX2012010198A (es) 2012-10-03
BR112012022258A2 (pt) 2016-10-25
ES2765418T3 (es) 2020-06-09
CU23982B1 (es) 2014-03-26
CA2976671A1 (en) 2011-09-09
EP3345615B1 (en) 2019-10-16
SG183443A1 (en) 2012-09-27
EA201290849A1 (ru) 2013-05-30
HRP20192295T1 (hr) 2020-03-20
JP2017035100A (ja) 2017-02-16
DK3345615T3 (da) 2020-01-20
PH12018500639A1 (en) 2019-07-29
EA201892184A1 (ru) 2019-03-29
CN105001335B (zh) 2019-10-25
CL2012002415A1 (es) 2013-08-23
PH12018500641A1 (en) 2019-07-29
CL2017003218A1 (es) 2018-06-08
CY1119410T1 (el) 2018-03-07
US20120329996A1 (en) 2012-12-27
ES2642512T3 (es) 2017-11-16
IL262444B (en) 2021-01-31
MY174760A (en) 2020-05-13
KR20130004586A (ko) 2013-01-11
CN110835373A (zh) 2020-02-25
CA2791685C (en) 2019-07-23
IL262444A (en) 2018-12-31
SMT201700454T1 (it) 2018-01-11
PT2542257T (pt) 2017-10-09
JP6475679B2 (ja) 2019-02-27
CA2976671C (en) 2021-01-12
US8481030B2 (en) 2013-07-09
EP2542257A4 (en) 2013-11-13
HK1232232A1 (zh) 2018-01-05
EP2542257A1 (en) 2013-01-09
USRE47150E1 (en) 2018-12-04
CU20120126A7 (es) 2013-01-30
JP2013520996A (ja) 2013-06-10
NZ602115A (en) 2014-12-24
SG10201903166PA (en) 2019-05-30
CA2791685A1 (en) 2011-09-09
AU2011223710B2 (en) 2016-04-14
US20120108796A1 (en) 2012-05-03
PE20160538A1 (es) 2016-05-19
CN107987166A (zh) 2018-05-04
EP3345615A1 (en) 2018-07-11
ME02894B (me) 2018-04-20
DOP2012000239A (es) 2013-08-15
CY1122476T1 (el) 2021-01-27
CN105001335A (zh) 2015-10-28
PH12018500640A1 (en) 2019-07-29
ME03578B (me) 2020-07-20
CR20120453A (es) 2013-02-27
HK1254947A1 (zh) 2019-08-02
HUE047173T2 (hu) 2020-04-28
JP2019089807A (ja) 2019-06-13
WO2011109452A1 (en) 2011-09-09
IL277391A (en) 2020-11-30
PT3345615T (pt) 2020-01-17
ECSP19025350A (es) 2019-04-30
AU2011223710A1 (en) 2012-09-20
SI2542257T1 (en) 2018-01-31
JP6025570B2 (ja) 2016-11-16
CN102939098A (zh) 2013-02-20
GT201200252A (es) 2014-04-03
LT2542257T (lt) 2017-11-27
CA3101298A1 (en) 2011-09-09
CN106188301A (zh) 2016-12-07
PL2542257T3 (pl) 2018-01-31
PH12012501742A1 (en) 2022-03-21

Similar Documents

Publication Publication Date Title
HUE036655T2 (hu) Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
IL283829A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
LTPA2019011I1 (lt) CGRP antikūnai
IL221408B (en) Monoclonal antibodies against c-met
LT3284754T (lt) Antikūnai prieš cd38
DK2521736T3 (da) Humaniserede antistoffer
DK2371923T3 (da) Aflejringshæmmer
PL2734552T3 (pl) Hamujące monoklonalne przeciwciała skierowane przeciwko czynnikowi xii/xiia i ich zastosowanie
PL3342786T3 (pl) Przeciwciało przeciwko dll3
SMT201700083B (it) Anticorpi monoclonali
EP2600227A4 (en) Input device
HRP20181360T1 (hr) Anti-cd28 humanizirana protutijela
CO6791565A2 (es) Anticuerpos anti-notch1
EP2728900A4 (en) INPUT DEVICE
HUE050858T2 (hu) VLA-4 ellenes antitestek
EP2617715A4 (en) GLYCINTRANSPORTERHEMMER
EP2687958A4 (en) INPUT DEVICE
FI20110214A0 (fi) Kääntörunko
FR2969807B1 (fr) Bobine d'allumage optimisee